journal article·2022-06-29Open access

Metal–Organic Coordination Polymer for Delivery of a Subunit Broadly Acting Influenza Vaccine

Meital Eckshtain-Levi, Cole J. Batty, Liubov M. Lifshits, Brandon McCammitt, Kathryn M. Moore, Eva A. Amouzougan, Rebeca T. Stiepel, Eliza Duggan, Ted M. Ross, Eric M. Bachelder, Kristy M. Ainslie

ACS Applied Materials & Interfaces· Volume 14· Issue 25

Abstract

A zinc-carnosine (ZnCar) metal–organic coordination polymer was fabricated in biologically relevant N-(2-hydroxyethyl)piperazine-N′-ethanesulfonic acid (HEPES) buffer for use as a vaccine platform. In vitro, ZnCar exhibited significantly less cytotoxicity than a well-established zeolitic imidazolate framework (ZIF-8). Adsorption of CpG on the ZnCar surface resulted in enhanced innate immune activation compared to soluble CpG. The model antigen ovalbumin (OVA) was encapsulated in ZnCar and exhibited acid-sensitive release in vitro. When injected intramuscularly on days 0 and 21 in C57BL/6 mice, OVA-specific serum total IgG and IgG1 were significantly greater in all groups with ZnCar and antigen compared to soluble controls. Th1-skewed IgG2c antibodies were significantly greater in OVA and CpG groups delivered with ZnCar for all time points, regardless of whether the antigen and adjuvant were co-formulated in one material or co-delivered in separate materials. When broadly acting Computationally Optimized Broadly Reactive Antigen (COBRA) P1 influenza hemagglutinin (HA) was ligated to ZnCar via its His-tag, significantly greater antibody levels were observed at all time points compared to soluble antigen and CpG. ZnCar-formulated antigen elicited increased peptide presentation to B3Z T cells in vitro and production of IL-2 after ex vivo antigen recall of splenocytes isolated from vaccinated mice. Overall, this work displays the formation of a zinc-carnosine metal–organic coordination polymer that can be applied as a platform for recombinant protein-based vaccines.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Biochemical effects in animals · Influenza Virus Research Studies · Hepatitis B Virus Studies

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States

North Carolina School of Science and Mathematics, Durham, North Carolina 27705, United States

Center for Vaccines and Immunology, University of Georgia, Athens, Georgia 30602, United States

Department of Infectious Diseases, University of Georgia, Athens, Georgia 30602, United States

Department of Microbiology and Immunology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, United States

Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Chapel Hill, North Carolina 27514, United States

Funding

Ford Foundation · National Institute of Allergy and Infectious Diseases · Division of Graduate Education

References (52)

Show source-provided references
1. 10.1021/acsami.8b2050410.1021/acsami.8b20504 ↗
2. 10.1073/pnas.21264399910.1073/pnas.212643999 ↗
3. 10.3389/fimmu.2019.0018810.3389/fimmu.2019.00188 ↗
4. 10.1073/pnas.090159210610.1073/pnas.0901592106 ↗
5. 10.1016/j.jconrel.2017.11.03010.1016/j.jconrel.2017.11.030 ↗
6. 10.1021/mp800068x10.1021/mp800068x ↗
7. 10.1002/ange.20130707410.1002/ange.201307074 ↗
8. Pullin T. M. · 2019
9. 10.1002/adhm.20160064210.1002/adhm.201600642 ↗
10. 10.1021/cg801381p10.1021/cg801381p ↗
11. 10.1021/acsami.1c0108910.1021/acsami.1c01089 ↗
12. 10.1021/acsnano.9b0597410.1021/acsnano.9b05974 ↗
13. 10.1016/j.ccr.2021.21397710.1016/j.ccr.2021.213977 ↗
14. 10.3201/eid1201.05125410.3201/eid1201.051254 ↗
15. CDC, 2009 H1n1 Pandemic (H1n1pdm09 Virus). Centers for Disease Control and Prevention, N. C. f. I. a. R. D. N., Ed. cdc.gov, 2019.
16. Janeway C. · 2001
17. 10.1128/JVI.03152-1510.1128/JVI.03152-15 ↗
18. 10.1103/PhysRev.56.97810.1103/PhysRev.56.978 ↗
19. 10.1016/j.abb.2016.04.01010.1016/j.abb.2016.04.010 ↗
20. 10.1107/S002188981301311310.1107/S0021889813013113 ↗
21. 10.1039/C9CE00757A10.1039/C9CE00757A ↗
22. 10.1021/acsami.1c0070610.1021/acsami.1c00706 ↗
23. 10.1016/j.biomaterials.2020.11998310.1016/j.biomaterials.2020.119983 ↗
24. 10.1016/j.jconrel.2019.02.03510.1016/j.jconrel.2019.02.035 ↗
25. 10.1002/adfm.20150499810.1002/adfm.201504998 ↗
26. 10.1021/acsnano.1c0309210.1021/acsnano.1c03092 ↗
27. 10.1073/pnas.90.11.494210.1073/pnas.90.11.4942 ↗
28. 10.1016/j.jconrel.2018.09.02010.1016/j.jconrel.2018.09.020 ↗
29. 10.1002/anbr.20200004110.1002/anbr.202000041 ↗
30. 10.1016/j.biomaterials.2019.03.01110.1016/j.biomaterials.2019.03.011 ↗
31. 10.1128/CVI.00152-0610.1128/CVI.00152-06 ↗
32. 10.1021/acsami.8b0168010.1021/acsami.8b01680 ↗
33. 10.1002/adfm.20160065010.1002/adfm.201600650 ↗
34. 10.1039/b807085g10.1039/b807085g ↗
35. 10.1128/JVI.03152-1510.1128/JVI.03152-15 ↗
36. 10.1371/journal.pone.020428410.1371/journal.pone.0204284 ↗
37. 10.1128/JVI.01349-1810.1128/JVI.01349-18 ↗
38. 10.4049/jimmunol.190037910.4049/jimmunol.1900379 ↗
39. 10.1038/ncomms824010.1038/ncomms8240 ↗
40. 10.1016/j.ijpharm.2016.08.03110.1016/j.ijpharm.2016.08.031 ↗
41. 10.1172/jci.insight.14462710.1172/jci.insight.144627 ↗
42. 10.1002/adtp.20200010010.1002/adtp.202000100 ↗
43. 10.1158/2326-6066.CIR-14-0019-T10.1158/2326-6066.CIR-14-0019-T ↗
44. 10.1016/j.vaccine.2010.11.06310.1016/j.vaccine.2010.11.063 ↗
45. 10.3389/fimmu.2019.0301810.3389/fimmu.2019.03018 ↗
46. 10.1016/j.vaccine.2020.03.02610.1016/j.vaccine.2020.03.026 ↗
47. 10.1016/j.vaccine.2012.10.05410.1016/j.vaccine.2012.10.054 ↗
48. 10.1371/journal.pone.001227910.1371/journal.pone.0012279 ↗
49. 10.1073/pnas.95.26.1555310.1073/pnas.95.26.15553 ↗
50. 10.1021/acsami.0c1027610.1021/acsami.0c10276 ↗
51. 10.1021/acs.molpharmaceut.8b0057910.1021/acs.molpharmaceut.8b00579 ↗
52. 10.1016/S0022-1759(98)00170-710.1016/S0022-1759(98)00170-7 ↗